Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07334860 | A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) | PHASE1 | ACTIVE NOT_RECRUITING | 16 | — | — | Feb 6, 2026 | May 28, 2026 | Mar 19, 2026 | 1 | United States |
| NCT07266818 | A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) | PHASE1 | COMPLETED | 30 | — | — | Dec 18, 2025 | Apr 9, 2026 | Apr 28, 2026 | 1 | United States |
| NCT06703463 | A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) | PHASE1 | COMPLETED | 16 | — | — | Oct 17, 2023 | Feb 2, 2024 | Nov 25, 2024 | 1 | United States |
| NCT06625840 | A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) | PHASE1 | COMPLETED | 16 | — | — | Sep 18, 2023 | May 8, 2024 | Oct 3, 2024 | 1 | United States |
Blood samples will be collected to determine the AUC0-inf of MK-1167.
Blood samples will be collected to determine the Cmax of MK-1167.
Blood samples will be collected to determine the AUC0-last of MK-1167.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
AUC0-inf of MK-1167 in plasma will be determined.
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.
Blood samples will be collected to determine the AUC0-24 of MK-1167.
Blood samples will be collected to determine the Cmax of MK-1167.
Blood samples will be collected to determine the C24 of MK-1167.
Blood samples will be collected to determine the Tmax of MK-1167.
Blood samples will be collected to determine the CL/F of MK-1167.
Blood samples will be collected to determine the Vz/F of MK-1167.
Blood samples will be collected to determine the t½ of MK-1167.
| Arm | Type | Description |
|---|---|---|
| Arm 1: MK-1167 Form 2 | EXPERIMENTAL | Participants receive MK-1167 Form 2 orally. |
| Arm 2: MK-1167 Form 1 | EXPERIMENTAL | Participants receive MK-1167 Form 1 orally. |
| MK-1167 | EXPERIMENTAL | MK-1167 administered orally |
| Placebo | PLACEBO_COMPARATOR | Placebo for MK-1167 administered orally |
| MK-1167 Period 1 | EXPERIMENTAL | On Day 1 a single dose of MK-1167 will be administered. |
| MK-1167 Period 2 | EXPERIMENTAL | There will be a washout of at least 35 days between MK-1167 dosing in Period 1 and the first diltiazem dose in Period 2. In Period 2, diltiazem will be administered once daily (QD) for 49 consecutive days with a single dose of MK-1167 coadministered on Day 3. |
| Panel A | EXPERIMENTAL | Participants receive a loading dose of MK-1167 or Placebo orally on day 1, followed by a once daily (QD) maintenance dose orally on days 2 to 16. |
| Panel B | EXPERIMENTAL | Participants receive a loading dose of MK-1167 or Placebo orally on days 1 to 3, followed by a QD maintenance dose orally on days 4 to 16. |
| Name | Type | Description |
|---|---|---|
| MK-1167 | DRUG | Oral administration |
| Placebo | DRUG | Oral capsule administered once daily |
| Diltiazem | DRUG | Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules. |
Inclusion Criteria: * Is in good health * Has a body mass index (BMI) ≥18 and ≤ 32 kg/m\^2, inclusive Exclusion Criteria: * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neuro...